Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLPRIT phase I/II study of CXCR4-directed theranostics in advanced lymphoproliferative cancers
2024-517639-35-00Phase 2Authorised
- Sponsor
- Klinikum rechts der Isar
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentixafor and 90Y-Pentixather in multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and transformed B-cell lymphoma, sponsored by Klinikum rechts der Isar. Primary endpoints: Maximum tolerated dose and Overall response rate. Planned start Oct 2024; status: authorised.
02
Drugs
pentixafor90Y-Pentixather
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)transformed B-cell lymphoma
Beyond the preview
Go deeper on 2024-517639-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517639-35-00.